Canada markets closed
  • S&P/TSX

    19,228.03
    -0.87 (-0.00%)
     
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • DOW

    33,800.60
    +297.00 (+0.89%)
     
  • CAD/USD

    0.7974
    +0.0013 (+0.16%)
     
  • CRUDE OIL

    59.34
    +0.02 (+0.03%)
     
  • BTC-CAD

    74,969.76
    -285.42 (-0.38%)
     
  • CMC Crypto 200

    1,235.89
    +8.35 (+0.68%)
     
  • GOLD FUTURES

    1,744.10
    -0.70 (-0.04%)
     
  • RUSSELL 2000

    2,243.47
    +0.87 (+0.04%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • NASDAQ

    13,900.19
    +70.89 (+0.51%)
     
  • VOLATILITY

    16.69
    -0.26 (-1.53%)
     
  • FTSE

    6,915.75
    -26.47 (-0.38%)
     
  • NIKKEI 225

    29,768.06
    +59.06 (+0.20%)
     
  • CAD/EUR

    0.6698
    +0.0021 (+0.31%)
     

SAB Biotherapeutics to Present at Upcoming March Investor Conferences

·2 min read

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced that Eddie J. Sullivan , PhD, co-founder, president and CEO, will present at two upcoming investor conferences.

  • H.C. Wainwright Global Life Sciences Conference available for on-demand viewing throughout the conference, starting at 7:00 a.m. ET on Tuesday, March 9, 2021

  • Credit Suisse 2021 Spring Private Company Showcase at 4:00 p.m. ET on Thursday, March 11, 2021, the presentation will be available for on-demand viewing afterwards

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed with initial funding supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant, influenza and an human immune globulin (IgG) for mediated diseases. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006090/en/

Contacts

Melissa Ullerich
Tel: 605-695-8350
mullerich@sabbiotherapeutics.com

Stern Investor Relations
Courtney Turiano
+1 212-362-1200
courtney.turiano@sternir.com